*4.14. Postoperative Adjuvant Chemotherapy in UBUC*

To evaluate the role of *MAP1B* expression in the response to adjuvant chemotherapy in UBUC patients, an independent cohort containing 70 patients with pT3 or pT4 disease or with nodal involvement received cisplatin-based adjuvant chemotherapy combined with vinblastine and were enrolled for further survival analysis (Table S3).

## *4.15. Statistical Analyses*

The Statistical Package for the Social Sciences version 12.0 software program (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. Differences between categorical parameters were assessed using the chi-squared or Fisher's exact test. The median H scores of *MAP1B* immunoreactivity were used as cutoff values to separate UTUC and UBUC into two subgroups of high and low *MAP1B* expression. Pearson's chi-squared test was used to compare the association between *MAP1B* expression and clinicopathological parameters. The Kaplan–Meier method was applied to estimate the effect of *MAP1B* expression on DSS and MFS. The survival curves were compared using the log-rank test. We used a Cox proportional-hazards model to identify independent predictors for DSS and MFS. In all figure legend, continuous parameters (such as MAP1B transcript expression in Figure 1, mitotic activity in Figure 2, *MAP1B* mRNA expression, relative proliferation, migration and invasion in Figure 4, apoptosis rate in Figure 6) were assessed using a t-test or Mann–Whitney–Wilcoxon test. Survival analysis (DSS and MFS) were performed using Kaplan-Meier plots and compared by the log-rank test. Statistical significance was set at *p* < 0.05.

#### **5. Conclusions**

In summary, the present study demonstrated that MAP1B overexpression was not only an indicator of unfavorable clinicopathological parameters, but also an independent prognostic factor able to predict poor DSS and MFS rates in patients with UTUC or UBUC. Additional studies must be conducted to elucidate the details of the biological significance of MAP1B and its encoded protein in UC oncogenesis for exploring possible MAP1B-targeted therapy for both kinds of UC.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2072-6694/12/3/630/s1, Table S1: Urothelial carcinoma enrolled to explore potential MAP1B mutation, Table S2: MAP1B mutations validated and primer sets, Table S3: Characters of independent UBUC patient cohorts receiving postoperative adjuvant chemotherapy.

**Author Contributions:** Conceptualization, T.-M.C., S.K.-H.H., W.-J.W., C.-F.L.; Methodology, B.-W.Y.; Formal analysis, T.-C.C.; Data curation, T.-C.C., S.K.-H.H., W.-J.W., C.-F.L.; Writing—original draft preparation, T.-M.C.; Writing—review and editing, C.-N.H.; Supervision, W.-M.L., C.-C.L.; Project administration, C.-F.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by Kaohsiung Medical University "Aim for the Top Universities," grant nos. KMU-TP104E31, KMU-TP105G00, KMU-TP105G01, and KMU-TP105G02; the Health and Welfare Surcharge of Tobacco Products, Ministry of Health and Welfare, grant no. MOHW105-TDU-B-212-134007l the Ministry of Science and Technology, grant no. MOST103-2314-B-037-067-MY3; Kaohsiung Medical University Hospital, grant nos. KMUH101-1R47 and KMUH102-2R42. KMU-KI109002 to WM.Li, WJ. Wu and CF. Li.

**Acknowledgments:** The authors gratefully acknowledge the assistance of all the members in our group and the BioBank of Chi Mei Medical center. The authors would like to thank Enago (www.enago.tw) for the English language review.

**Conflicts of Interest:** The authors declare no conflict of interest.
